INS and metabolic dysfunction-associated steatotic liver disease: Inhibition of ACC1 as well as mitochondrial ACC2, which produces mitochondrial malonyl-CoA and thereby inhibits FAO, was found to ameliorate NAFLD and improve glucose metabolism through suppression of DNL, enhancement of FAO, and promotion of insulin signaling in the liver (60, 61).